Proteomics

Dataset Information

0

Liver proteome upon in vivo N-acetylgalactosamine-conjugated antisense oligonucleotide silencing of ceramide synthase 2

ABSTRACT: Mouse liver proteome was investigated upon in vivo mouse treatment with a N-acetylgalactosamine-conjugated antisense oligonucleotide engineered to silence ceramide synthase 2 specifically in hepatocytes in vivo. The data is a part of a study on the involvement of ceramide enzymatic machinery in cardiovasular disorders and its potential as a target for the disease treatment.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Liver

SUBMITTER: Sergey Kovalchuk  

LAB HEAD: Sergey Igorevich Kovalchuk

PROVIDER: PXD025957 | Pride | 2023-05-10

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
LUM2_02085_KS_LiverChrister_60ug-10fr_TMTMS2_2hG_FC-150-45In2_fr1.raw Raw
LUM2_02086_KS_LiverChrister_60ug-10fr_TMTMS2_2hG_FC-150-45In2_fr2.raw Raw
LUM2_02087_KS_LiverChrister_60ug-10fr_TMTMS2_2hG_FC-150-45In2_fr3.raw Raw
LUM2_02088_KS_LiverChrister_60ug-10fr_TMTMS2_2hG_FC-150-45In2_fr4.raw Raw
LUM2_02089_KS_LiverChrister_60ug-10fr_TMTMS2_2hG_FC-150-45In2_fr5.raw Raw
Items per page:
1 - 5 of 16
altmetric image

Publications

Silencing of ceramide synthase 2 in hepatocytes modulates plasma ceramide biomarkers predictive of cardiovascular death.

Schmidt Steffen S   Gallego Sandra F SF   Zelnik Iris Daphne ID   Kovalchuk Sergey S   Albæk Nanna N   Sprenger Richard R RR   Øverup Charlotte C   Pewzner-Jung Yael Y   Futerman Anthony H AH   Lindholm Marie W MW   Jensen Ole N ON   Ejsing Christer S CS  

Molecular therapy : the journal of the American Society of Gene Therapy 20210814 4

Emerging clinical data show that three ceramide molecules, Cer d18:1/16:0, Cer d18:1/24:1, and Cer d18:1/24:0, are biomarkers of a fatal outcome in patients with cardiovascular disease. This finding raises basic questions about their metabolic origin, their contribution to disease pathogenesis, and the utility of targeting the underlying enzymatic machinery for treatment of cardiometabolic disorders. Here, we outline the development of a potent N-acetylgalactosamine-conjugated antisense oligonuc  ...[more]

Similar Datasets

Proteomics Mass Spectrometry Methods and Mathematical PK/PD Model for Decision Tree-Guided Covalent Drug Development
2025-01-23 | PXD046903 | Pride
Transcriptomics Hepatic gene expression changes following antisense oligonucleotide-based inhibition of miR-29a
2012-08-22 | E-GEOD-40261 | biostudies-arrayexpress
Unknown Oligonucleotide conjugated multi-functional adeno-associated viruses.
| S-EPMC5827683 | biostudies-literature
Unknown Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol.
| S-EPMC4345304 | biostudies-literature
Unknown Sensitive Protein Detection Using Site-Specifically Oligonucleotide-Conjugated Nanobodies.
| S-EPMC9310004 | biostudies-literature
Proteomics Elucidating the RNA-protein Interactomes of Target RNAs in Tissue
2023-07-30 | PXD038809 | Pride
Proteomics Small extracellular vesicles from young plasma reverse age-related functional declines by improving mitochondrial energy metabolism
2024-03-31 | PXD030350 | Pride
Transcriptomics Gene expression profiling of effect of Yap inhibition in a genetically engineered mouse model of hepatocellular carcinoma
2015-03-07 | E-GEOD-65665 | biostudies-arrayexpress
Unknown Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice.
| S-EPMC7192618 | biostudies-literature
Proteomics Adaption of oxidative phosphorylation machinery compensates hepatic lipotoxicity in early stages of MAFLD, isolated mitochondria PMID:3543314
2022-08-02 | PXD032211 | Pride